Catalent has acquired Italian biologics and oral dose facility from Bristol-Myers Squibb

January 9, 2020

Catalent has completed the purchase of Bristol-Myers Squibb’s biologics, sterile, and oral solid dose product manufacturing and packaging facility in Anagni, Italy.

Catalent (Somerset, NJ) has completed the purchase of Bristol-Myers Squibb’s biologics, sterile, and oral solid dose product manufacturing and packaging facility in Anagni, Italy. The 305,000 square-foot facility offers extensive capabilities in aseptic liquid and powder filling for biologics and sterile products across multiple vial sizes, as well as comprehensive primary and secondary packaging solutions, including serialization, to support product launches for oral solids, sterile, and biologics products. The new facility complements Catalent’s existing European oral and solid dose development and manufacturing network with includes facilities in Schorndorf and Eberbach, Germany, Nottingham and Swindon, UK, Benheim, France, and Aprilia, Italy.

“The Anagni facility supplements our European commercial supply capabilities and will integrate well with our existing global early development and clinical supply sites to smooth the transition from development to commercial supply,” said Alessandro Maselli, Catalent’s president and chief operating officer, in a press release. “Anagni provides our European customers with great biologics and oral dose capabilities that can help us reduce time-to-market, simplify tech transfers, and minimize program risk.”

Catalent says that it plans to make further investments in the site’s growth. The firm will also continue to manufacture the existing Bristol-Myers Squibb product portfolio currently produced at the site.